Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lacy, MQ, Hayman, SR, Gertz, MA, Short, KD, Dispenzieri, A, Kumar, S, Greipp, PR, Lust, JA, Russell, SJ, Dingli, D, Zeldenrust, S, Fonseca, R, Bergsagel, PL, Roy, V, Mikhael, JR, Stewart, AK, Laumann, K, Allred, JB, Mandrekar, SJ, Rajkumar, SV, Buadi, F
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978257/
https://ncbi.nlm.nih.gov/pubmed/20827286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.190
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados